Johns Hopkins University

The Penn State Research Foundation

Randen Patterson

Damian Brett Van Rossum

Solomon H Snyder

Mark Donowitz

Asif K Mustafa

Anutosh Chakraborty

Krishna Juluri

Michael Koldobskiy

Nicholas Constantine Zachos

Katherine Sixt

A synthetic peptide modeled on the IRCX binding area of NHE3, is a competitive inhibitor of the IRCX and both stimulates basal NHE3 activity and prevents elevated Caand cAMP inhibition of NHE3. Methods of its preparation and use in the prevention and/or treatment of gastrointestinal disease, such as diarrhea are provided.

[object Object]

Anti-cancer drugs are identified by screening for agents and compounds which inhibit the binding of HSP90 and IP6K2. In vitro and in vivo assays can be used. Any phenomenon associated with the binding or inhibition can be monitored, including cell death, subcellular localization, catalytic activity of IP6K2, and IP7 formation.

Regulation of cell survival by HSP90 and IP6K2

Growing community of inventors

University Park, PA, United States of America

Randen Patterson